Form 4: Apeiron Investment Boosts ATAI Stake

Sentiment:

Insider Ownership Report 18 August 2025 6:00 PM

Apeiron Investment Group and Christian Angermayer reported a significant purchase of ATAI Life Sciences common shares, increasing their beneficial ownership.

Better than expectedA significant purchase of common shares by a 10% owner and director indicates strong confidence in the company's valuation and future performance.The transaction increases the beneficial ownership of key insiders, aligning their interests more closely with other shareholders.

Summary

Apeiron Investment Group Ltd. and Christian Angermayer, both directors and 10% owners of ATAI Life Sciences N.V., reported a purchase of common shares.
On August 14, 2025, 8,675,799 common shares were acquired at a price of $2.19 per share.
Following this transaction, Apeiron Investment Group Ltd. indirectly beneficially owns 51,045,214 common shares.
Additionally, 1,799,302 common shares are indirectly beneficially owned by Apeiron Presight Capital Fund II, L.P.

Sentiment

Score: 8

Explanation: The significant purchase of shares by a 10% owner and director signals strong confidence in the company's future prospects and valuation.

Positives

Significant insider purchase by a 10% owner and director, signaling strong confidence in the company's future.
The acquisition of 8,675,799 common shares at $2.19 per share represents a substantial investment.

Negatives

Risks

Future Outlook

Management Comments

Industry Context

This insider purchase by a significant shareholder and director suggests strong internal confidence in ATAI Life Sciences N.V.'s prospects within the biotechnology and life sciences sector, particularly in the psychedelic-inspired therapeutics space.

Comparison to Industry Standards

Management Changes

Role	Previous Person	New Person	Effective Date	Reason

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment

Legal Proceedings

Related Party Transactions

The acquisition of 8,675,799 common shares by Apeiron Investment Group Ltd., a 10% owner and director, constitutes a related party transaction.

Stakeholder Impact

Shareholders may view this significant insider purchase as a positive signal, potentially increasing investor confidence and demand for the stock.

Next Steps

Key Dates

Date	Description
08/14/2025	Date of common shares acquisition by Apeiron Investment Group Ltd.
08/18/2025	Filing date of the Statement of Changes in Beneficial Ownership.

Recommendation

strong buy

The substantial purchase of common shares by a 10% owner and director, Christian Angermayer and Apeiron Investment Group Ltd., at a price of $2.19 per share, indicates strong conviction in ATAI Life Sciences N.V.'s future prospects and current valuation. This insider buying activity often signals that those with the most intimate knowledge of the company believe the stock is undervalued or poised for significant growth, making it a compelling "strong buy" signal for investors.

Keywords

ATAI, Apeiron Investment Group, Christian Angermayer, insider trading, stock purchase, beneficial ownership, Form 4, life sciences

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.